Auteur : Rosenberg, David R / Gershon, Samuel

Édition : 3rd edition

Maison d'édition : Wiley-Blackwell

Date de publication : 2012

Collation : xx, 453 p.

ISBN : 9780470973769

Langue : Anglais

Table des matières : 1. Historical perspectives on child and adolescent psychopharmacology -- 2. Pharmacoepidemiology of psychotropic medications in youth -- 3. Off-label prescribing of drugs in child and adolescent psychiatry -- 4. The use of generic drugs in pediatric psychopharmacology -- 5. Psychoactive drug use in children : basic concepts in clinical pharmacology -- 6. Psychostimulants -- 7. Tricyclic antidepressants and monoamine oxidase inhibitors for the treatment of child and adolescent psychiatric disorders -- 8. Selective serotonin reuptake inhibitors (SSRIs) -- 9. Novel (atypical) antidepressants -- 10. Antipsychotic agents -- 11. Lithium -- 12. Anticonvulsants used in child and adolescent psychiatric disorders -- 13. Anxiolytics -- 14. Adrenergic agents in child and adolescent psychiatry -- 15. Atypical psychopharmacologic strategies -- 16. Psychopharmacology in prescool children -- 17. Combination pharmacotherapy for psychiatric disorders in children and adolescents

Résumé : This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

Mots-clés : Psychotropes / Chimiothérapie / Pharmacologie

Cote : QV 77 R813p 2012